Roles of phosphatidylinositol-3-kinases signaling pathway in inflammation-related cancer: Impact of rs10889677 variant and buparlisib in colitis-associated cancer

doi:10.3748/wjg.v29.i40.5543

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 29, Issue 40

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2983)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-8) series, Tables (1-1) series.

Item

Count

PDF

WORD

HTML

1037

Figures (1-8)

232

Tables (1-1)

172

Sum=1555

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

172

Download

553

Sum=725

Publishing Process of This Article

Item

Count

Browse

143

Download

423

Sum=566

Oct 28, 2023 (publication date) through Jun 16, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Gastroenterol. Oct 28, 2023; 29(40): 5543-5556
Published online Oct 28, 2023. doi: 10.3748/wjg.v29.i40.5543

Full Size Figure Download Figure

Figure 5 Histological structure assessment. The range of the histologic scores varied from 0 (no inflammation) to 4 (extensive inflammation). Magnification is 40 ×.

Citation: Razali NN, Raja Ali RA, Muhammad Nawawi KN, Yahaya A, Mohd Rathi ND, Mokhtar NM. Roles of phosphatidylinositol-3-kinases signaling pathway in inflammation-related cancer: Impact of rs10889677 variant and buparlisib in colitis-associated cancer. World J Gastroenterol 2023; 29(40): 5543-5556
URL: https://www.wjgnet.com/1007-9327/full/v29/i40/5543.htm
DOI: https://dx.doi.org/10.3748/wjg.v29.i40.5543